Skip to main content
NCBI home page
Heart logoLink to Heart
. 1996 Nov;76(3 Suppl 3):7–12. doi: 10.1136/hrt.76.3_suppl_3.7

The renin-angiotensin system and the heart: a historical review

Stephen J Cleland 1, John L Reid 1
PMCID: PMC484481  PMID: 8977359

Full text

PDF
7

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BROWN J. J., DAVIES D. L., LEVER A. F., ROBERTSON J. I. Influence of sodium loading and sodium depletion on plasma-renin in man. Lancet. 1963 Aug 10;2(7302):278–279. doi: 10.1016/s0140-6736(63)90176-4. [DOI] [PubMed] [Google Scholar]
  2. BROWN J. J., DAVIES D. L., LEVER A. F., ROBERTSON J. I. VARIATIONS IN PLASMA RENIN CONCENTRATION IN SEVERAL PHYSIOLOGICAL AND PATHOLOGICAL STATES. Can Med Assoc J. 1964 Jan 25;90:201–206. [PMC free article] [PubMed] [Google Scholar]
  3. BUCHBORN E., KOCZOREK K. R., KOHLER M., WOLFF H. P. Uber die Aldosteronaktivität und Natriumretention bei Herzkranken und ihre pathophysiologische Bedeutung. Klin Wochenschr. 1956 Nov 1;34(41-42):1105–1114. doi: 10.1007/BF01466775. [DOI] [PubMed] [Google Scholar]
  4. Baker K. M., Aceto J. F. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol. 1990 Aug;259(2 Pt 2):H610–H618. doi: 10.1152/ajpheart.1990.259.2.H610. [DOI] [PubMed] [Google Scholar]
  5. Baker K. M., Khosla M. C. Cardiac and vascular actions of decapeptide angiotensin analogs. J Pharmacol Exp Ther. 1986 Dec;239(3):790–796. [PubMed] [Google Scholar]
  6. Bakhle Y. S. Conversion of angiotensin I to angiotensin II by cell-free extracts of dog lung. Nature. 1968 Nov 30;220(5170):919–921. doi: 10.1038/220919a0. [DOI] [PubMed] [Google Scholar]
  7. Boyd G. W., Fitz A. E., Adamson A. R., Peart W. S. Radioimmunoassay determination of plasma-renin activity. Lancet. 1969 Feb 1;1(7588):213–218. doi: 10.1016/s0140-6736(69)91237-9. [DOI] [PubMed] [Google Scholar]
  8. Brown A. J., Casals-Stenzel J., Gofford S., Lever A. F., Morton J. J. Comparison of fast and slow pressor effects of angiotensin II in the conscious rat. Am J Physiol. 1981 Sep;241(3):H381–H388. doi: 10.1152/ajpheart.1981.241.3.H381. [DOI] [PubMed] [Google Scholar]
  9. Brown J. J., Brown W. C., Fraser R., Lever A. F., Morton J. J., Robertson J. I., Rosei E. A., Trust P. M. The effects of the angiotensin II antagonist saralasin on blood pressure and plasma aldosterone in man in relation to the prevailing plasma angiotensin II concentration. Prog Biochem Pharmacol. 1976;12:230–241. [PubMed] [Google Scholar]
  10. Brown J. J., Casals-Stenzel J., Cumming A. M., Davies D. L., Fraser R., Lever A. F., Morton J. J., Semple P. F., Tree M., Robertson J. I. Angiotensin II, aldosterone and arterial pressure: a quantitative approach. Arthur C. Corcoran Memorial Lecture. Hypertension. 1979 May-Jun;1(3):159–179. doi: 10.1161/01.hyp.1.3.159. [DOI] [PubMed] [Google Scholar]
  11. Brunner H. R., Laragh J. H., Baer L., Newton M. A., Goodwin F. T., Krakoff L. R., Bard R. H., Bühler F. R. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med. 1972 Mar 2;286(9):441–449. doi: 10.1056/NEJM197203022860901. [DOI] [PubMed] [Google Scholar]
  12. Cambien F., Poirier O., Lecerf L., Evans A., Cambou J. P., Arveiler D., Luc G., Bard J. M., Bara L., Ricard S. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992 Oct 15;359(6396):641–644. doi: 10.1038/359641a0. [DOI] [PubMed] [Google Scholar]
  13. Campbell-Boswell M., Robertson A. L., Jr Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro. Exp Mol Pathol. 1981 Oct;35(2):265–276. doi: 10.1016/0014-4800(81)90066-6. [DOI] [PubMed] [Google Scholar]
  14. Campbell D. J. Circulating and tissue angiotensin systems. J Clin Invest. 1987 Jan;79(1):1–6. doi: 10.1172/JCI112768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Casale P. N., Devereux R. B., Milner M., Zullo G., Harshfield G. A., Pickering T. G., Laragh J. H. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 1986 Aug;105(2):173–178. doi: 10.7326/0003-4819-105-2-173. [DOI] [PubMed] [Google Scholar]
  16. Chobanian A. V., Haudenschild C. C., Nickerson C., Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1990 Mar;15(3):327–331. doi: 10.1161/01.hyp.15.3.327. [DOI] [PubMed] [Google Scholar]
  17. Cody R. J., Atlas S. A., Laragh J. H., Kubo S. H., Covit A. B., Ryman K. S., Shaknovich A., Pondolfino K., Clark M., Camargo M. J. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest. 1986 Nov;78(5):1362–1374. doi: 10.1172/JCI112723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Cushman D. W., Wang F. L., Fung W. C., Harvey C. M., DeForrest J. M. Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens. 1989 Apr;2(4):294–306. doi: 10.1093/ajh/2.4.294. [DOI] [PubMed] [Google Scholar]
  19. DAVIS J. O., HARTROFT P. M., TITUS E. O., CARPENTER C. C., AYERS C. R., SPIEGEL H. E. The role of the renin-angiotensin system in the control of aldosterone secretion. J Clin Invest. 1962 Feb;41:378–389. doi: 10.1172/JCI104492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. DAVIS J. O. Mechanisms regulating the secretion and metabolism of aldosterone in experimental secondary hyperaldosteronism. Recent Prog Horm Res. 1961;17:293–352. [PubMed] [Google Scholar]
  21. Dahlöf B., Pennert K., Hansson L. Regression of left ventricular hypertrophy--a meta-analysis. Clin Exp Hypertens A. 1992;14(1-2):173–180. doi: 10.3109/10641969209036180. [DOI] [PubMed] [Google Scholar]
  22. Davis R., Ribner H. S., Keung E., Sonnenblick E. H., LeJemtel T. H. Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme. N Engl J Med. 1979 Jul 19;301(3):117–121. doi: 10.1056/NEJM197907193010301. [DOI] [PubMed] [Google Scholar]
  23. Devereux R. B., Pickering T. G., Cody R. J., Laragh J. H. Relation of renin-angiotensin system activity to left ventricular hypertrophy and function in experimental and human hypertension. J Clin Hypertens. 1987 Mar;3(1):87–103. [PubMed] [Google Scholar]
  24. ELLIOTT D. F., PEART W. S. Amino-acid sequence in a hypertensin. Nature. 1956 Mar 17;177(4507):527–528. doi: 10.1038/177527a0. [DOI] [PubMed] [Google Scholar]
  25. Engel S. L., Schaeffer T. R., Waugh M. H., Rubin B. Effects of the nonapeptide SQ 20881 on blood pressure of rats with experimental renovascular hypertension. Proc Soc Exp Biol Med. 1973 Jun;143(2):483–487. doi: 10.3181/00379727-143-37348. [DOI] [PubMed] [Google Scholar]
  26. Ertl G. Coronary vasoconstriction in experimental myocardial ischemia. J Cardiovasc Pharmacol. 1987;9 (Suppl 2):S9–17. doi: 10.1097/00005344-198700002-00004. [DOI] [PubMed] [Google Scholar]
  27. FERREIRA S. H. A BRADYKININ-POTENTIATING FACTOR (BPF) PRESENT IN THE VENOM OF BOTHROPS JARARCA. Br J Pharmacol Chemother. 1965 Feb;24:163–169. doi: 10.1111/j.1476-5381.1965.tb02091.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Faxon D. P., Creager M. A., Halperin J. L., Sussman H. A., Gavras H., Ryan T. J. The effect of angiotensin converting enzyme inhibition of coronary blood flow and hemodynamics in patients without coronary artery disease. Int J Cardiol. 1982;2(2):251–262. doi: 10.1016/0167-5273(82)90040-7. [DOI] [PubMed] [Google Scholar]
  29. Floras J. S., Hassan M. O., Jones J. V., Osikowska B. A., Sever P. S., Sleight P. Consequences of impaired arterial baroreflexes in essential hypertension: effects on pressor responses, plasma noradrenaline and blood pressure variability. J Hypertens. 1988 Jul;6(7):525–535. doi: 10.1097/00004872-198807000-00003. [DOI] [PubMed] [Google Scholar]
  30. Foult J. M., Tavolaro O., Antony I., Nitenberg A. Direct myocardial and coronary effects of enalaprilat in patients with dilated cardiomyopathy: assessment by a bilateral intracoronary infusion technique. Circulation. 1988 Feb;77(2):337–344. doi: 10.1161/01.cir.77.2.337. [DOI] [PubMed] [Google Scholar]
  31. Furberg C. D., Yusuf S. Effect of vasodilators on survival in chronic congestive heart failure. Am J Cardiol. 1985 Apr 1;55(8):1110–1113. doi: 10.1016/0002-9149(85)90756-8. [DOI] [PubMed] [Google Scholar]
  32. Gavras H., Gavras I. Cardioprotective potential of angiotensin converting enzyme inhibitors. J Hypertens. 1991 May;9(5):385–392. doi: 10.1097/00004872-199105000-00001. [DOI] [PubMed] [Google Scholar]
  33. Gavras H., Kremer D., Brown J. J., Gray B., Lever A. F., MacAdam R. F., medina A., Morton J. J., Robertson J. I. Angiotensin- and norepinephrine-induced myocardial lesions: experimental and clinical studies in rabbits and man. Am Heart J. 1975 Mar;89(3):321–332. doi: 10.1016/0002-8703(75)90082-4. [DOI] [PubMed] [Google Scholar]
  34. HARTROFT P. M., HARTROFT W. S. Studies on renal juxtaglomerular cells. II. Correlation of the degree of granulation of juxtaglomerular cells with width of the zone glomerulosa of the adrenal cortex. J Exp Med. 1955 Aug 1;102(2):205–212. doi: 10.1084/jem.102.2.205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Hayduk K., Boucher R., Genest J. Renin activity content in various tissues od dogs under different physiopathological states. Proc Soc Exp Biol Med. 1970 May;134(1):252–255. doi: 10.3181/00379727-134-34770. [DOI] [PubMed] [Google Scholar]
  36. Hirsch A. T., Talsness C. E., Schunkert H., Paul M., Dzau V. J. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res. 1991 Aug;69(2):475–482. doi: 10.1161/01.res.69.2.475. [DOI] [PubMed] [Google Scholar]
  37. Holtz J. Pathophysiology of heart failure and the renin-angiotensin-system. Basic Res Cardiol. 1993;88 (Suppl 1):183–201. doi: 10.1007/978-3-642-72497-8_13. [DOI] [PubMed] [Google Scholar]
  38. Inagami T., Misono K., Michelakis A. M. Definitive evidence for similarity in the active site of renin and acidic protease. Biochem Biophys Res Commun. 1974 Jan 23;56(2):503–509. doi: 10.1016/0006-291x(74)90871-7. [DOI] [PubMed] [Google Scholar]
  39. Jin M., Wilhelm M. J., Lang R. E., Unger T., Lindpaintner K., Ganten D. Endogenous tissue renin-angiotensin systems. From molecular biology to therapy. Am J Med. 1988 Mar 11;84(3A):28–36. doi: 10.1016/0002-9343(88)90202-1. [DOI] [PubMed] [Google Scholar]
  40. Johnson J. A., Davis J. O. Effects of a specific competitive antagonist of angiotensin II on arterial pressure and adrenal steroid secretion in dogs. Circ Res. 1973 May 5;32(Suppl):159–168. [PubMed] [Google Scholar]
  41. KOCH-WESER J. NATURE OF THE INOTROPIC ACTION OF ANGIOTENSIN ON VENTRICULAR MYOCARDIUM. Circ Res. 1965 Mar;16:230–237. doi: 10.1161/01.res.16.3.230. [DOI] [PubMed] [Google Scholar]
  42. Kremer D., Lindop G., Brown W. C., Morton J. J., Robertson J. I. Angiotensin-induced myocardial necrosis and renal failure in the rabbit: distribution of lesions and severity in relation to plasma angiotensin II concentration and arterial pressure. Cardiovasc Res. 1981 Jan;15(1):43–46. doi: 10.1093/cvr/15.1.43. [DOI] [PubMed] [Google Scholar]
  43. LARAGH J. H., ANGERS M., KELLY W. G., LIEBERMAN S. Hypotensive agents and pressor substances. The effect of epinephrine, norepinephrine, angiotensin II, and others on the secretory rate of aldosterone in man. JAMA. 1960 Sep 17;174:234–240. doi: 10.1001/jama.1960.03030030014003. [DOI] [PubMed] [Google Scholar]
  44. Landis E. M., Montgomery H., Sparkman D. THE EFFECTS OF PRESSOR DRUGS AND OF SALINE KIDNEY EXTRACTS ON BLOOD PRESSURE AND SKIN TEMPERATURE. J Clin Invest. 1938 Mar;17(2):189–206. doi: 10.1172/JCI100944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Laragh J. H. Lewis K. Dahl Memorial Lecture. The renin system and four lines fo hypertension research. Nephron heterogeneity, the calcium connection, the prorenin vasodilator limb, and plasma renin and heart attack. Hypertension. 1992 Sep;20(3):267–279. doi: 10.1161/01.hyp.20.3.267. [DOI] [PubMed] [Google Scholar]
  46. Lever A. F., Robertson J. I., Tree M. The estimation of renin in plasma by an enzyme kinetic technique. Biochem J. 1964 May;91(2):346–352. doi: 10.1042/bj0910346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Levy D., Garrison R. J., Savage D. D., Kannel W. B., Castelli W. P. Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study. Ann Intern Med. 1989 Jan 15;110(2):101–107. doi: 10.7326/0003-4819-110-2-101. [DOI] [PubMed] [Google Scholar]
  48. Lindpaintner K., Wilhelm M. J., Jin M., Unger T., Lang R. E., Schoelkens B. A., Ganten D. Tissue renin-angiotensin systems: focus on the heart. J Hypertens Suppl. 1987 Jul;5(2):S33–S38. doi: 10.1097/00004872-198707002-00007. [DOI] [PubMed] [Google Scholar]
  49. Linz W., Schölkens B. A., Han Y. F. Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts. J Cardiovasc Pharmacol. 1986;8 (Suppl 10):S91–S99. doi: 10.1097/00005344-198600101-00017. [DOI] [PubMed] [Google Scholar]
  50. MULROW P. J., GANONG W. F. Stimulation of aldosterone secretion by angiotensisn. II. A preliminary report. Yale J Biol Med. 1961 Apr;33:386–395. [PMC free article] [PubMed] [Google Scholar]
  51. MacFadyen R. J., Reid J. L. Angiotensin receptor antagonists as a treatment for hypertension. J Hypertens. 1994 Dec;12(12):1333–1338. [PubMed] [Google Scholar]
  52. Magrini F., Reggiani P., Roberts N., Meazza R., Ciulla M., Zanchetti A. Effects of angiotensin and angiotensin blockade on coronary circulation and coronary reserve. Am J Med. 1988 Mar 11;84(3A):55–60. doi: 10.1016/0002-9343(88)90205-7. [DOI] [PubMed] [Google Scholar]
  53. Mancia G., Romero J. C., Shepherd J. T. Continuous inhibition of renin release in dogs by vagally innervated receptors in the cardiopulmonary region. Circ Res. 1975 Apr;36(4):529–535. doi: 10.1161/01.res.36.4.529. [DOI] [PubMed] [Google Scholar]
  54. McAlpine H. M., Cobbe S. M. Neuroendocrine changes in acute myocardial infarction. Am J Med. 1988 Mar 11;84(3A):61–66. doi: 10.1016/0002-9343(88)90206-9. [DOI] [PubMed] [Google Scholar]
  55. Morgan H. E., Baker K. M. Cardiac hypertrophy. Mechanical, neural, and endocrine dependence. Circulation. 1991 Jan;83(1):13–25. doi: 10.1161/01.cir.83.1.13. [DOI] [PubMed] [Google Scholar]
  56. Needleman P., Marshall G. R., Sobel B. E. Hormone interactions in the isolated rabbit heart. Synthesis and coronary vasomotor effects of prostaglandins, angiotensin, and bradykinin. Circ Res. 1975 Dec;37(6):802–808. doi: 10.1161/01.res.37.6.802. [DOI] [PubMed] [Google Scholar]
  57. Oelkers W., Brown J. J., Fraser R., Lever A. F., Morton J. J., Robertson J. I. Sensitization of the adrenal cortex to angiotensin II in sodium-deplete man. Circ Res. 1974 Jan;34(1):69–77. doi: 10.1161/01.res.40.4.69. [DOI] [PubMed] [Google Scholar]
  58. Oparil S., Haber E. The renin-angiotensin system (first of two parts). N Engl J Med. 1974 Aug 22;291(8):389–401. doi: 10.1056/NEJM197408222910805. [DOI] [PubMed] [Google Scholar]
  59. Pals D. T., Masucci F. D., Sipos F., Denning G. S., Jr A specific competitive antagonist of the vascular action of angiotensin. II. Circ Res. 1971 Dec;29(6):664–672. doi: 10.1161/01.res.29.6.664. [DOI] [PubMed] [Google Scholar]
  60. Pfeffer J. M., Pfeffer M. A. Angiotensin converting enzyme inhibition and ventricular remodeling in heart failure. Am J Med. 1988 Mar 11;84(3A):37–44. doi: 10.1016/0002-9343(88)90203-3. [DOI] [PubMed] [Google Scholar]
  61. Pfeffer J. M., Pfeffer M. A., Mirsky I., Braunwald E. Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc Natl Acad Sci U S A. 1982 May;79(10):3310–3314. doi: 10.1073/pnas.79.10.3310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Pfeffer M. A., Braunwald E., Moyé L. A., Basta L., Brown E. J., Jr, Cuddy T. E., Davis B. R., Geltman E. M., Goldman S., Flaker G. C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669–677. doi: 10.1056/NEJM199209033271001. [DOI] [PubMed] [Google Scholar]
  63. Poulsen K., Burton J., Haber E. Competitive inhibitors of renin. A review. Prog Biochem Pharmacol. 1976;12:135–141. [PubMed] [Google Scholar]
  64. Powell J. S., Clozel J. P., Müller R. K., Kuhn H., Hefti F., Hosang M., Baumgartner H. R. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989 Jul 14;245(4914):186–188. doi: 10.1126/science.2526370. [DOI] [PubMed] [Google Scholar]
  65. Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990 Oct;86(4):1343–1346. doi: 10.1172/JCI114844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. SKEGGS L. T., Jr, KAHN J. R., LENTZ K., SHUMWAY N. P. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med. 1957 Sep 1;106(3):439–453. doi: 10.1084/jem.106.3.439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. SKEGGS L. T., Jr, KAHN J. R., SHUMWAY N. P. The preparation and function of the hypertensin-converting enzyme. J Exp Med. 1956 Mar 1;103(3):295–299. doi: 10.1084/jem.103.3.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Szelke M., Leckie B., Hallett A., Jones D. M., Sueiras J., Atrash B., Lever A. F. Potent new inhibitors of human renin. Nature. 1982 Oct 7;299(5883):555–557. doi: 10.1038/299555a0. [DOI] [PubMed] [Google Scholar]
  69. Turini G. A., Brunner H. R., Gribic M., Waeber B., Gavras H. Improvement of chronic congestive heart-failure by oral captopril. Lancet. 1979 Jun 9;1(8128):1213–1215. doi: 10.1016/s0140-6736(79)91897-x. [DOI] [PubMed] [Google Scholar]
  70. Unger T., Ganten D., Lang R. E., Schölkens B. A. Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe498 and MK421, in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1984 Sep-Oct;6(5):872–880. doi: 10.1097/00005344-198409000-00021. [DOI] [PubMed] [Google Scholar]
  71. Yang H. Y., Erdös E. G., Levin Y. Characterization of a dipeptide hydrolase (kininase II: angiotensin I converting enzyme). J Pharmacol Exp Ther. 1971 Apr;177(1):291–300. [PubMed] [Google Scholar]
  72. ZIMMERMAN B. G. Effect of acute sympathectomy on responses to angiotensin and norepinephrine. Circ Res. 1962 Nov;11:780–787. doi: 10.1161/01.res.11.5.780. [DOI] [PubMed] [Google Scholar]
  73. de Bold A. J., Borenstein H. B., Veress A. T., Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981 Jan 5;28(1):89–94. doi: 10.1016/0024-3205(81)90370-2. [DOI] [PubMed] [Google Scholar]
  74. deGraeff P. A., deLangen C. D., van Gilst W. H., Bel K., Scholtens E., Kingma J. H., Wesseling H. Protective effects of captopril against ischemia/reperfusion-induced ventricular arrhythmias in vitro and in vivo. Am J Med. 1988 Mar 11;84(3A):67–74. doi: 10.1016/0002-9343(88)90207-0. [DOI] [PubMed] [Google Scholar]
  75. ter Meulen V., Koprowski H., Iwasaki Y., Käckell Y. M., Müller D. Fusion of cultured multiple-sclerosis brain cells with indicator cells: presence of nucleocapsids and virions and isolation of parainfluenza-type virus. Lancet. 1972 Jul 1;2(7766):1–5. doi: 10.1016/s0140-6736(72)91273-1. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES